As we previously reported, earlier this year Merck announced that it would be spinning off its women’s health, biosimilars, and established brands businesses into a standalone company. This month, Merck completed the spinoff, creating Organon. Organon’s portfolio contains about 60 treatments and products, and mainly focuses on ex-US markets. Organon also plans to acquire Alydia Health, which focuses on prevention of maternal morbidity and mortality caused by abnormal postpartum bleeding, as part of its focus on women’s health treatments
The post Merck Completes Organon Spinoff appeared first on Big Molecule Watch.